Results 21 to 30 of about 73,633 (314)

Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models

open access: yesScience Translational Medicine, 2021
Normalizing the tumor microenvironment with losartan prevents tumor-induced hearing loss and enhances radiation response in schwannoma rodent models.
Limeng Wu   +23 more
semanticscholar   +1 more source

Losartan Improves Memory, Neurogenesis and Cell Motility in Transgenic Alzheimer’s Mice

open access: yesPharmaceuticals, 2021
Angiotensin receptor blockers (ARBs) have demonstrated multiple neuroprotective benefits in Alzheimer’s disease (AD) models. However, their beneficial effects on memory deficits, cholinergic activity, neurogenesis and Amyloid beta (Aβ) clearance reveal ...
H. Drews   +13 more
semanticscholar   +1 more source

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

open access: yesNew England Journal of Medicine, 2001
BACKGROUND Diabetic nephropathy is the leading cause of end-stage renal disease. Interruption of the renin-angiotensin system slows the progression of renal disease in patients with type 1 diabetes, but similar data are not available for patients with ...
B. Brenner   +9 more
semanticscholar   +1 more source

Temporal profile and mechanisms of the prompt sympathoexcitation following coronary ligation in Wistar rats [PDF]

open access: yes, 2014
Our aim was to assess the timing and mechanisms of the sympathoexcitation that occurs immediately after coronary ligation. We recorded thoracic sympathetic (tSNA) and phrenic activities, heart rate (HR) and perfusion pressure in Wistar rats subjected to ...
Abdala, Ana Paula   +5 more
core   +7 more sources

Combined therapeutic benefit of mitochondria-targeted antioxidant, MitoQ10, and angiotensin receptor blocker, losartan, on cardiovascular function [PDF]

open access: yes, 2014
<b>Objective:</b><p></p> Mitochondria-derived reactive oxygen species (ROS) play important roles in the development of cardiovascular disease highlighting the need for novel targeted therapies.
Adlam   +41 more
core   +1 more source

Losartan-induced Pancreatitis [PDF]

open access: yesCureus, 2019
Drug-induced acute pancreatitis (DIAP) is a rare gastrointestinal condition but well-known in the medical literature. The medications have been classified into four subgroups (Classes I-IV) depending upon the propensity of the cases discussed in the literature, interval time period between drug initiation to pancreatitis, and reaction to the drug with ...
Rameez Shaukat   +2 more
openaire   +3 more sources

Atenolol versus losartan in children and young adults with Marfan's syndrome [PDF]

open access: yes, 2014
BACKGROUND : Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers.
Atz, A.M.   +33 more
core   +2 more sources

Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.

open access: yesJAMA Oncology, 2019
Importance Patients with locally advanced pancreatic cancer have historically poor outcomes. Evaluation of a total neoadjuvant approach is warranted. Objective To evaluate the margin-negative (R0) resection rate of neoadjuvant FOLFIRINOX (fluorouracil,
Janet E. Murphy   +30 more
semanticscholar   +1 more source

Inhibition of Glycoprotein VI Clustering by Collagen as a Mechanism of Inhibiting Collagen-Induced Platelet Responses: The Example of Losartan. [PDF]

open access: yesPLoS ONE, 2015
Exposure of platelets to collagen triggers the formation of a platelet clot. Pharmacological agents capable of inhibiting platelet activation by collagen are thus of potential therapeutic interest.
Peng Jiang   +5 more
doaj   +1 more source

Angiotensin II type 1 receptor antagonists alleviate muscle pathology in the mouse model for laminin-alpha2-deficient congenital muscular dystrophy (MDC1A) [PDF]

open access: yes, 2012
BACKGROUND: Laminin-alpha2-deficient congenital muscular dystrophy (MDC1A) is a severe muscle-wasting disease for which no curative treatment is available.
Lin, Shuo   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy